Treatment of Frontotemporal Dementias

doi:10.1017/9781108985055.022

Chapter 22 - Treatment of Frontotemporal Dementias

from Section 3 - Treatment of the Dementias

Published online by Cambridge University Press: 17 November 2025

Doris Chen ,

Lawren VandeVrede and

Adam L. Boxer

Edited by

Bruce L. Miller and

Bradley F. Boeve

Show author details

Bruce L. Miller: Affiliation:
University of California, San Francisco
Bradley F. Boeve: Affiliation:
Mayo Clinic, Minnesota

Book contents

Get access

Summary

There are currently no disease-modifying therapies for the frontotemporal dementias (FTD), but there are ways to enhance the lives of patients and their families by targeting the symptoms and stressors that arise. Accurate diagnosis and education are important for patients and families, and safety measures are necessary to prevent harm. Advanced care planning and caregiver support are critical for a chronic disease. Non-pharmacological treatments, such as behavioral management and a multidisciplinary approach, are recommended. The pharmacotherapy options include antidepressants, antipsychotics, and other medications, but there is limited evidence to support their use. This chapter provides information on clinical trials in FTD, including patient selection and enrollment, trial design, and potential disease-modifying treatments being explored. Further research is needed to develop effective treatments for FTD.

Keywords

frontotemporal dementias (FTD)neurodegenerative diseases safety caregiver support behavioral management antidepressants antipsychotics parkinsonism medications clinical trials autosomal dominant FTD sporadic FTD

Information

Type: Chapter
Information: The Behavioral Neurology of Dementia , pp. 373 - 386

DOI: https://doi.org/10.1017/9781108985055.022 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Ducharme, S, Dols, A, Laforce, R, et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain. 2020;143(6):1632–1650.10.1093/brain/awaa018CrossRef Google Scholar PubMed

Fletcher, PD, Downey, LE, Golden, HL, et al. Pain and temperature processing in dementia: a clinical and neuroanatomical analysis. Brain. 2015;138(Pt 11):3360–3372.10.1093/brain/awv276CrossRef Google Scholar PubMed

Galvin, JE, Howard, DH, Denny, SS, Dickinson, S, Tatton, N. The social and economic burden of frontotemporal degeneration. Neurology. 2017;89(20):2049–2056.CrossRef Google Scholar PubMed

Ayalon, L, Gum, AM, Feliciano, L, Arean, PA. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med. 2006;166(20):2182–2188.10.1001/archinte.166.20.2182CrossRef Google Scholar PubMed

Brodaty, H, Arasaratnam, C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;169(9):946–953.CrossRef Google Scholar PubMed

Fossey, J, Ballard, C, Juszczak, E, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ. 2006;332(7544):756–761.10.1136/bmj.38782.575868.7CCrossRef Google Scholar PubMed

Hall, GR, Buckwalter, KC. Progressively Lowered Stress Threshold: a conceptual model for care of adults with Alzheimer’s disease. Arch Psychiatr Nurs. 1987;1(6):399–406.Google Scholar PubMed

Cohen-Mansfield, J, Marx, MS, Rosenthal, AS. A description of agitation in a nursing home. J Gerontol. 1989;44(3):M77–84.10.1093/geronj/44.3.M77CrossRef Google Scholar PubMed

Kales, HC, Gitlin, LN, Lyketsos, CG, Detroit Expert Panel on Assessment and Management of Neuropsychiatric Symptoms of Dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–769.10.1111/jgs.12730CrossRef Google Scholar PubMed

Fortinsky, RH, Gitlin, LN, Pizzi, LT, et al. Translation of the Care of Persons with Dementia in their Environments (COPE) intervention in a publicly-funded home care context: Rationale and research design. Contemp Clin Trials. 2016;49:155–165.10.1016/j.cct.2016.07.006CrossRef Google Scholar

Gitlin, LN, Winter, L, Dennis, MP, Hodgson, N, Hauck, WW. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention. J Am Geriatr Soc. 2010;58(8):1465–1474.10.1111/j.1532-5415.2010.02971.xCrossRef Google Scholar PubMed

Hepburn, KW, Lewis, M, Sherman, CW, Tornatore, J. The savvy caregiver program: developing and testing a transportable dementia family caregiver training program. Gerontologist. 2003;43(6):908–915.10.1093/geront/43.6.908CrossRef Google Scholar PubMed

Barton, C, Merrilees, J, Ketelle, R, Wilkins, S, Miller, B. Implementation of advanced practice nurse clinic for management of behavioral symptoms in dementia: a dyadic intervention (innovative practice). Dementia (London). 2014;13(5):686–696.10.1177/1471301213519895CrossRef Google Scholar PubMed

Possin, KL, Merrilees, JJ, Dulaney, S, et al. Effect of collaborative dementia care via telephone and internet on quality of life, caregiver well-being, and health care use: the Care Ecosystem Randomized Clinical Trial. JAMA Intern Med. 2019;179(12):1648–1657.10.1001/jamainternmed.2019.4101CrossRef Google Scholar PubMed

Bernstein, A, Merrilees, J, Dulaney, S, et al. Using care navigation to address caregiver burden in dementia: a qualitative case study analysis. Alzheimers Dement (N Y). 2020;6(1):e12010.10.1002/trc2.12010CrossRef Google Scholar PubMed

Gitlin, LN, Winter, L, Vause Earland, T, et al. The Tailored Activity Program to reduce behavioral symptoms in individuals with dementia: feasibility, acceptability, and replication potential. Gerontologist. 2009;49(3):428–439.10.1093/geront/gnp087CrossRef Google Scholar PubMed

Henry, ML, Hubbard, HI, Grasso, SM, et al. Retraining speech production and fluency in non-fluent/agrammatic primary progressive aphasia. Brain. 2018;141(6):1799–1814.10.1093/brain/awy101CrossRef Google Scholar PubMed

Morris, MC, Tangney, CC, Wang, Y, et al. MIND diet slows cognitive decline with aging. Alzheimers Dement. 2015;11(9):1015–1022.10.1016/j.jalz.2015.04.011CrossRef Google Scholar PubMed

Johnson, JK, Chow, ML. Hearing and music in dementia. Handb Clin Neurol. 2015;129:667–687.Google Scholar PubMed

Erkkinen, MG, Zuniga, RG, Pardo, CC, Miller, BL, Miller, ZA. Artistic renaissance in frontotemporal dementia. JAMA. 2018;319(13):1304–1306.10.1001/jama.2017.19501CrossRef Google Scholar PubMed

Miller, BL, Hou, CE. Portraits of artists: emergence of visual creativity in dementia. Arch Neurol. 2004;61(6):842–844.10.1001/archneur.61.6.842CrossRef Google Scholar PubMed

Huey, ED, Putnam, KT, Grafman, J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66(1):17–22.10.1212/01.wnl.0000191304.55196.4dCrossRef Google Scholar PubMed

Murley, AG, Rowe, JB. Neurotransmitter deficits from frontotemporal lobar degeneration. Brain. 2018;141(5):1263–1285.10.1093/brain/awx327CrossRef Google Scholar PubMed

Hughes, LE, Rittman, T, Regenthal, R, Robbins, TW, Rowe, JB. Improving response inhibition systems in frontotemporal dementia with citalopram. Brain. 2015;138(Pt 7):1961–1975.10.1093/brain/awv133CrossRef Google Scholar PubMed

Herrmann, N, Black, SE, Chow, T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry. 2012;20(9):789–797.10.1097/JGP.0b013e31823033f3CrossRef Google Scholar PubMed

Mendez, MF, Shapira, JS, Miller, BL. Stereotypical movements and frontotemporal dementia. Mov Disord. 2005;20(6):742–745.10.1002/mds.20465CrossRef Google Scholar PubMed

Prodan, CI, Monnot, M, Ross, ED. Behavioural abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline. J Neurol Neurosurg Psychiatry. 2009;80(12):1416–1417.10.1136/jnnp.2009.173260CrossRef Google Scholar PubMed

Moretti, R, Torre, P, Antonello, RM, Cazzato, G, Bava, A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49(1):13–19.10.1159/000067021CrossRef Google Scholar PubMed

Deakin, JB, Rahman, S, Nestor, PJ, Hodges, JR, Sahakian, BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl). 2004;172(4):400–408.Google Scholar

Ikeda, M, Shigenobu, K, Fukuhara, R, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord. 2004;17(3):117–121.10.1159/000076343CrossRef Google Scholar PubMed

Lebert, F, Stekke, W, Hasenbroekx, C, Pasquier, F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17(4):355–359.10.1159/000077171CrossRef Google Scholar PubMed

Furlan, JC, Henri-Bhargava, A, Freedman, M. Clomipramine in the treatment of compulsive behavior in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2014;28(1):95–98.10.1097/WAD.0b013e318265c104CrossRef Google Scholar PubMed

Chow, TW, Mendez, MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2002;17(5):267–272.10.1177/153331750201700504CrossRef Google Scholar PubMed

Kales, HC, Kim, HM, Zivin, K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71–79.CrossRef Google Scholar PubMed

Kurlan, R, Cummings, J, Raman, R, Thal, L, Alzheimer’s Disease Cooperative Study G. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356–1363.10.1212/01.wnl.0000260060.60870.89CrossRef Google Scholar PubMed

Weiden, PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007;13(1):13–24.10.1097/00131746-200701000-00003CrossRef Google Scholar

Reeves, RR, Perry, CL. Aripiprazole for sexually inappropriate vocalizations in frontotemporal dementia. J Clin Psychopharmacol. 2013;33(1):145–146.10.1097/01.jcp.0000426190.64916.3bCrossRef Google Scholar PubMed

Moretti, R, Torre, P, Antonello, RM, et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18(4):205–214.10.1177/153331750301800410CrossRef Google Scholar PubMed

Kimura, T, Takamatsu, J. Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms. Geriatr Gerontol Int. 2013;13(2):506–507.10.1111/j.1447-0594.2012.00956.xCrossRef Google Scholar PubMed

Kertesz, A, Morlog, D, Light, M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25(2):178–185.10.1159/000113034CrossRef Google Scholar PubMed

Moretti, R, Torre, P, Antonello, RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21(14):931–793.10.2165/00002512-200421140-00003CrossRef Google Scholar PubMed

Boxer, AL, Knopman, DS, Kaufer, DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(2):149–256.10.1016/S1474-4422(12)70320-4CrossRef Google Scholar PubMed

Johnson, NA, Rademaker, A, Weintraub, S, et al. Pilot trial of memantine in primary progressive aphasia. Alzheimer Dis Assoc Disord. 2010;24(3):308.10.1097/WAD.0b013e3181cf468dCrossRef Google Scholar PubMed

Rahman, S, Robbins, TW, Hodges, JR, et al. Methylphenidate (“Ritalin”) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. 2006;31(3):651–658.10.1038/sj.npp.1300886CrossRef Google Scholar PubMed

Huey, ED, Garcia, C, Wassermann, EM, Tierney, MC, Grafman, J. Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry. 2008;69(12):1981198–2.10.4088/JCP.v69n1219aCrossRef Google Scholar PubMed

Armstrong, MJ. Diagnosis and treatment of corticobasal degeneration. Curr Treat Options Neurol. 2014;16(3):282.10.1007/s11940-013-0282-1CrossRef Google Scholar PubMed

McFarland, NR. Diagnostic approach to atypical parkinsonian syndromes. Continuum (Minneap Minn). 2016;22(4 Movement Disorders):1117–1142.10.1212/CON.0000000000000348CrossRef Google Scholar PubMed

Rittman, T, Coyle-Gilchrist, IT, Rowe, JB. Managing cognition in progressive supranuclear palsy. Neurodegener Dis Manag. 2016;6(6):499–508.10.2217/nmt-2016-0027CrossRef Google Scholar PubMed

Fremont, R, Manoochehri, M, Armstrong, NM, et al. Tolcapone treatment for cognitive and behavioral symptoms in behavioral variant frontotemporal dementia: a placebo-controlled crossover study. J Alzheimers Dis. 2020;75(4):1391–1403.10.3233/JAD-191265CrossRef Google Scholar PubMed

Moretti, R, Torre, P, Antonello, RM, Cazzato, G, Bava, A. Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation. Int J Geriatr Psychiatry. 2002;17(4):391–392.10.1002/gps.602CrossRef Google Scholar PubMed

VandeVrede, L, Ljubenkov, PA, Rojas, JC, Welch, AE, Boxer, AL. Four-repeat tauopathies: current management and future treatments. Neurotherapeutics. 2020;17(4):1563–1581.10.1007/s13311-020-00888-5CrossRef Google Scholar PubMed

Cummings, JL, Lyketsos, CG, Peskind, ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242–1254.10.1001/jama.2015.10214CrossRef Google Scholar PubMed

Finger, EC, MacKinley, J, Blair, M, et al. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. Neurology. 2015;84(2):174–181.10.1212/WNL.0000000000001133CrossRef Google Scholar PubMed

Kimura, T, Hayashida, H, Furukawa, H, Takamatsu, J. Pilot study of pharmacological treatment for frontotemporal dementia: effect of Yokukansan on behavioral symptoms. Psychiatry Clin Neurosci. 2010;64(2):207–210.10.1111/j.1440-1819.2010.02072.xCrossRef Google Scholar PubMed

Devanand, DP, Pelton, GH, D’Antonio, K, et al. Low-dose lithium treatment for agitation and psychosis in Alzheimer disease and frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2017;31(1):73–75.10.1097/WAD.0000000000000161CrossRef Google Scholar PubMed

Onyike, CU, Diehl-Schmid, J. The epidemiology of frontotemporal dementia. Int Rev Psychiatry. 2013;25(2):130–137.10.3109/09540261.2013.776523CrossRef Google Scholar PubMed

Perry, DC, Brown, JA, Possin, KL, et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain. 2017;140(12):3329–3345.10.1093/brain/awx254CrossRef Google Scholar PubMed

Hoglinger, GU, Respondek, G, Stamelou, M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853–864.10.1002/mds.26987CrossRef Google Scholar PubMed

Boxer, AL, Gold, M, Feldman, H, et al. New directions in clinical trials for frontotemporal lobar degeneration: methods and outcome measures. Alzheimers Dement. 2020;16(1):131–143.10.1016/j.jalz.2019.06.4956CrossRef Google Scholar PubMed

VandeVrede, L, Dale, ML, Fields, S, et al. Open-label phase 1 futility studies of salsalate and young plasma in progressive supranuclear palsy. Mov Disord Clin Pract. 2020;7(4):440–447.10.1002/mdc3.12940CrossRef Google Scholar

Tsai, RM, Miller, Z, Koestler, M, et al. Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial. JAMA Neurol. 2019;77(2):215–224.10.1001/jamaneurol.2019.3812CrossRef Google Scholar

Berry, SM, Connor, JT, Lewis, RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015;313(16):1619–1620.10.1001/jama.2015.2316CrossRef Google Scholar PubMed

Staffaroni, AM, Ljubenkov, PA, Kornak, J, et al. Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. Brain. 2019;142(2):443–459.10.1093/brain/awy319CrossRef Google Scholar PubMed

Toller, G, Ranasinghe, K, Cobigo, Y, et al. Revised Self-Monitoring Scale: a potential endpoint for frontotemporal dementia clinical trials. Neurology. 2020;94(22):e2384–e2395.10.1212/WNL.0000000000009451CrossRef Google Scholar

Rabinovici, GD, Gatsonis, C, Apgar, C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286–1294.10.1001/jama.2019.2000CrossRef Google Scholar PubMed

Thijssen, EH, La Joie, R, Wolf, A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387–397.10.1038/s41591-020-0762-2CrossRef Google Scholar PubMed

Ljubenkov, PA, Staffaroni, AM, Rojas, JC, et al. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Ann Clin Transl Neurol. 2018;5(10):1250–1263.10.1002/acn3.643CrossRef Google Scholar PubMed

Meeter, LH, Patzke, H, Loewen, G, et al. Progranulin levels in plasma and cerebrospinal fluid in granulin mutation carriers. Dement Geriatr Cogn Dis Extra. 2016;6(2):330–340.10.1159/000447738CrossRef Google Scholar PubMed

Gendron, TF, Chew, J, Stankowski, JN, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med. 2017;9(383).10.1126/scitranslmed.aai7866CrossRef Google Scholar PubMed

Palmqvist, S, Janelidze, S, Quiroz, YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772–781.10.1001/jama.2020.12134CrossRef Google Scholar PubMed

Kao, AW, McKay, A, Singh, PP, Brunet, A, Huang, EJ. Progranulin, lysosomal regulation and neurodegenerative disease. Nat Rev Neurosci. 2017;18(6):325–333.10.1038/nrn.2017.36CrossRef Google Scholar PubMed

Sha, SJ, Miller, ZA, Min, SW, et al. An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations. Alzheimers Dement (N Y). 2017;3(4):507–512.10.1016/j.trci.2017.08.002CrossRef Google Scholar PubMed

Ljubenkov, PA, Edwards, L, Iaccarino, L, et al. Effect of the histone deacetylase inhibitor FRM-0334 on progranulin levels in patients with progranulin gene haploinsufficiency: a randomized clinical trial. JAMA Netw Open. 2021;4(9):e2125584.10.1001/jamanetworkopen.2021.25584CrossRef Google Scholar PubMed

DeVos, SL, Miller, TM. Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics. 2013;10(3):486–497.10.1007/s13311-013-0194-5CrossRef Google Scholar PubMed

VandeVrede, L, Boxer, AL, Polydoro, M. Targeting tau: Clinical trials and novel therapeutic approaches. Neurosci Lett. 2020;731:134919.10.1016/j.neulet.2020.134919CrossRef Google Scholar PubMed

Apetauerova, D, Scala, SA, Hamill, RW, et al. CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e266.10.1212/NXI.0000000000000266CrossRef Google Scholar PubMed

Bensimon, G, Ludolph, A, Agid, Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009;132(Pt 1):156–171.10.1093/brain/awn291CrossRef Google Scholar PubMed

Boxer, AL, Lang, AE, Grossman, M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13(7):676–685.10.1016/S1474-4422(14)70088-2CrossRef Google Scholar PubMed

Gauthier, S, Feldman, HH, Schneider, LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388(10062):2873–2884.10.1016/S0140-6736(16)31275-2CrossRef Google Scholar PubMed

Nuebling, G, Hensler, M, Paul, S, et al. PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. J Neurol. 2016;263(8):1565–1574.10.1007/s00415-016-8169-1CrossRef Google Scholar PubMed

Tolosa, E, Litvan, I, Höglinger, GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29(4):470–478.10.1002/mds.25824CrossRef Google Scholar PubMed

Tsai, RM, Miller, Z, Koestler, M, et al. Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial. JAMA Neurol. 2020;77(2):215–224.10.1001/jamaneurol.2019.3812CrossRef Google Scholar PubMed

Dam, T, Boxer, AL, Golbe, LI, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021;27(8):1451–1457.10.1038/s41591-021-01455-xCrossRef Google Scholar PubMed

Höglinger, GU, Litvan, I, Mendonca, N, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(3):182–192.10.1016/S1474-4422(20)30489-0CrossRef Google Scholar PubMed

Accessibility standard: WCAG 2.1 AA

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

The HTML of this chapter complies with version 2.1 of the Web Content Accessibility Guidelines (WCAG), covering newer accessibility requirements and improved user experiences and achieves the intermediate (AA) level of WCAG compliance, covering a wider range of accessibility requirements.

Content Navigation

Table of contents navigation
Allows you to navigate directly to chapters, sections, or non‐text items through a linked table of contents, reducing the need for extensive scrolling.

Index navigation
Provides an interactive index, letting you go straight to where a term or subject appears in the text without manual searching.

Reading Order & Textual Equivalents

Single logical reading order
You will encounter all content (including footnotes, captions, etc.) in a clear, sequential flow, making it easier to follow with assistive tools like screen readers.

Short alternative textual descriptions
You get concise descriptions (for images, charts, or media clips), ensuring you do not miss crucial information when visual or audio elements are not accessible.

Visual Accessibility

Use of colour is not sole means of conveying information
You will still understand key ideas or prompts without relying solely on colour, which is especially helpful if you have colour vision deficiencies.

Structural and Technical Features

ARIA roles provided
You gain clarity from ARIA (Accessible Rich Internet Applications) roles and attributes, as they help assistive technologies interpret how each part of the content functions.